S'abonner

Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial - 24/10/24

Doi : 10.1016/S1473-3099(24)00375-X 
Isabel Leroux-Roels, ProfMD a, Chittappen Kandiyil Prajeeth, PhD b, Amare Aregay, PhD b, Niranjana Nair, MSc b, Guus F Rimmelzwaan, ProfPhD b, Albert D M E Osterhaus, ProfPhD b, c, Simone Kardinahl, PhD d, Sabrina Pelz, PhD d, Stephan Bauer, PhD d, Valentino D’Onofrio, PhD a, Azhar Alhatemi, MD a, Bart Jacobs, MD a, Fien De Boever, MSc a, Sharon Porrez, MSc a, Gwenn Waerlop, PhD a, Carine Punt, MSc e, Bart Hendriks, BSc c, Ellemieke von Mauw, MSc c, Sandra van de Water, BSc f, Jose Harders-Westerveen, BSc f, Barry Rockx, PhD f, Lucien van Keulen, DVM f, Jeroen Kortekaas, PhD f, Geert Leroux-Roels, ProfPhD a, Paul J Wichgers Schreur, PhD e, f,
a Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium 
b Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine, Hannover, Germany 
c CR2O, Maarssen, Netherlands 
d IDT Biologika, Dessau-Rosslau, Germany 
e BunyaVax, Lelystad, Netherlands 
f Wageningen Bioveterinary Research, Lelystad, Netherlands 

* Correspondence to: Dr Paul J Wichgers Schreur, Wageningen Bioveterinary Research, Lelystad 8221 RA, Netherlands Wageningen Bioveterinary Research Lelystad RA 8221 Netherlands

Summary

Background

Rift Valley fever virus, a pathogen to ruminants, camelids, and humans, is an emerging mosquito-borne bunyavirus currently endemic to Africa and the Arabian Peninsula. Although animals are primarily infected via mosquito bites, humans mainly become infected following contact with infected tissues or fluids of infected animals. There is an urgent need for adequate countermeasures, especially for humans, because effective therapeutics or vaccines are not yet available. Here we assessed the safety, tolerability, and immunogenicity of a next-generation, four-segmented, live-attenuated vaccine candidate, referred to as hRVFV-4s, in humans.

Methods

A first-in-human, single-centre, randomised, double-blind, placebo-controlled trial was done in Belgium in which a single dose of hRVFV-4s was administered to healthy volunteers aged 18–45 years. Participants were randomly assigned using an interactive web response system. The study population encompassed 75 participants naive to Rift Valley fever virus infection, divided over three dosage groups (cohorts) of 25 participants each. All participants were followed up until 6 months. Using a staggered dose escalating approach, 20 individuals of each cohort were injected in the deltoid muscle of the non-dominant arm with either 104 (low dose), 105 (medium dose), or 106 (high dose) of 50% tissue culture infectious dose of hRVFV-4s as based on animal data, and five individuals per cohort received formulation buffer as a placebo. Primary outcome measures in the intention-to-treat population were adverse events and tolerability. Secondary outcome measures were vaccine-induced viraemia, vaccine virus shedding, Rift Valley fever virus nucleocapsid antibody responses (with ELISA), and neutralising antibody titres. Furthermore, exploratory objectives included the assessment of cellular immune responses by ELISpot. The trial was registered with the EU Clinical Trials Register, 2022-501460-17-00.

Findings

Between August and December, 2022, all 75 participants were vaccinated. No serious adverse events or vaccine-related severe adverse events were reported. Pain at the injection site (51 [85%] of 60 participants) was most frequently reported as solicited local adverse event, and headache (28 [47%] of 60) and fatigue (28 [47%] of 60) as solicited systemic adverse events in the active group. No vaccine virus RNA was detected in any of the blood, saliva, urine, or semen samples. Rift Valley fever virus nucleocapsid antibody responses were detected in most participants who were vaccinated with hRVFV-4s (43 [72%] of 60 on day 14) irrespective of the administered dose. In contrast, a clear dose–response relationship was observed for neutralising antibodies on day 28 with four (20%) of 20 participants responding in the low-dose group, 13 (65%) of 20 responding in the medium-dose group, and all participants (20 [100%] of 20) responding in the high-dose group. Consistent with the antibody responses, cellular immune responses against the nucleocapsid protein were detected in all dose groups, whereas a more dose-dependent response was observed for the Gn and Gc surface glycoproteins. Neutralising antibody titres declined over time, whereas nucleocapsid antibody responses remained relatively stable for at least 6 months.

Interpretation

The hRVFV-4s vaccine showed a high safety profile and excellent tolerability across all tested dose regimens, eliciting robust immune responses, particularly with the high-dose administration. The findings strongly support further clinical development of this candidate vaccine for human use.

Funding

The Coalition for Epidemic Preparedness Innovations with support from the EU Horizon 2020 programme.

Le texte complet de cet article est disponible en PDF.

Plan


© 2024  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 24 - N° 11

P. 1245-1253 - novembre 2024 Retour au numéro
Article précédent Article précédent
  • Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil
  • Mauricio L Nogueira, Monica A T Cintra, José A Moreira, Elizabeth G Patiño, Patricia Emilia Braga, Juliana C V Tenório, Lucas Bassolli de Oliveira Alves, Vanessa Infante, Daniela Haydee Ramos Silveira, Marcus Vínicius Guimarães de Lacerda, Dhelio Batista Pereira, Allex Jardim da Fonseca, Ricardo Queiroz Gurgel, Ivo Castelo-Branco Coelho, Cor Jesus Fernandes Fontes, Ernesto T A Marques, Gustavo Adolfo Sierra Romero, Mauro Martins Teixeira, André M Siqueira, Viviane Sampaio Boaventura, Fabiano Ramos, Erivaldo Elias Júnior, José Cassio de Moraes, Stephen S Whitehead, Alejandra Esteves-Jaramillo, Tulin Shekar, Jung-Jin Lee, Julieta Macey, Sabrina Gozlan Kelner, Beth-Ann G Coller, Fernanda Castro Boulos, Esper G Kallás, Phase 3 Butantan-DV Working Group, Wuelton Monteiro, Joabi Nascimento, Rosilene Ruffato, Eduardo Garbin, Érica Cristina da Silva, Solange Cunha da Silva, Anna Paula Ioris, Antonia Francileuda Casarin, Volfânio Andrade, Vitor Menezes, Flávio Henrique Dourado de Macêdo, Guilherme Alves de Lima Henn, Andréa de Almeida Coêlho, Luciano Teixeira Gomes, Tiago Rodrigues Viana, Pedro de Carvalho Ferreira, Ana Maria Aguiar dos Santos, Irassandra Rooze Pereira Uchôa Cavalcanti de Aquino, Rafael Dhalia, Karla Andreia Mëtte Waldrich Tauil, Valéria Gonçalves Santos, Camilla dos Santos Mota, Helton Santiago, Lisia Esper, Ultimo Libanio, Cassia Fernanda Estofolete, Samuel Noah Scamardi, Paula Patrícia de Freitas Chama, Barbara Azevedo, Clarisse Bressan, Patricia Brasil, Aldina Barral, Antonio Bandeira, Daniela Paixão, Angela Carvalho Freitas, Pedro Henrique Fernandes Moreira de Figueiredo, Luara Teófilo Pignati, Cristina Bonorino, Larissa Sanches, Isabelli Guasso, Vanessa Terezinha Gubert, Jéssica Melo Silva da Silveira, Christiane Herold de Jesus, Sonia Regina de Almeida, Maria do Carmo Sampaio Tavares Timenetsky, Cecilia Luisa Simões Santos
| Article suivant Article suivant
  • Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial
  • Ahmed H Fahal, Eiman Siddig Ahmed, Sahar Mubarak Bakhiet, Osama Elhadi Bakhiet, Lamis Ahmed Fahal, Abubakar Ahmed Mohamed, El Semani Widaa Mohamedelamin, Mustafa El Nour Bahar, Hadil Yassir Attalla, Emmanuel Edwar Siddig, Najwa A Mhmoud, Ahmed Mudawi Musa, Wendy W J van de Sande, Bruno Scherrer, Peelen Oyieko, Thaddaeus W Egondi, Kevin O Onyango, Katsura Hata, Wan-Yu Chu, Thomas P C Dorlo, Roger J Brüggemann, Borna A Nyaoke, Nathalie Strub-Wourgaft, Eduard E Zijlstra

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.